Saving patients from severe heart failure

The ICOMS FlowMaker® is a novel intracardiac assist device designed to improve the quality of life for severe heart failure patients, aiming for EU market entry by 2026 through clinical trials.

Subsidie
€ 2.500.000
2022

Projectdetails

Introduction

The ICOMS FlowMaker® is the first intracardiac assist device that overcomes all shortcomings of current and under development devices and restores patient's quality of life.

Design and Functionality

Its design perfectly fits all the needs of patients suffering from severe heart failure. Implanted inside the left ventricle and synchronized with the natural heartbeat, it assists the heart to push blood in a physiological way.

Advantages

  • The very low electrical consumption allows for wireless functioning.
  • With no driveline crossing the skin, the risk of infection is suppressed.
  • Without bypass to aorta and thanks to its pulsatile mode, the risk of bleeding is very low.

Market Need

The ICOMS FlowMaker® addresses the market of severe heart failure, where 95% of patients are left without any solution.

Project Aim

The aim of the project is to conduct the clinical trials to enter the EU market in 2026, then the US market, allowing to finally achieve EU sovereignty in severe heart failure treatment.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.500.000
Totale projectbegroting€ 9.903.923

Tijdlijn

Startdatum1-10-2022
Einddatum31-3-2025
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • FINEHEARTpenvoerder

Land(en)

France

Vergelijkbare projecten binnen EIC Accelerator

EIC Accelerator

Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients

Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.

€ 2.500.000
EIC Accelerator

A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients

reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.

€ 2.499.999
EIC Accelerator

Innovative, minimally invasive device to support the natural movement of the heart in heart failure patients

Syntach CS is an innovative implantable device that restores natural heart movement in patients with left ventricular heart failure, enhancing cardiac function through synchronized support.

€ 2.500.000
EIC Accelerator

The first heart failure therapy management point-of-care device with multiplex and multimodal sensor

CardioCap is a handheld POC device that uses a finger-prick blood sample to simultaneously assess heart failure severity through four biomarkers, aiming to reduce re-hospitalization and mortality rates by 30%.

€ 2.499.999
EIC Accelerator

Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoring

The Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations.

€ 2.299.633

Vergelijkbare projecten uit andere regelingen

Mkb-innovati...

Mechanical design concept for Cardiac Recovery Assist Device

CardiacBooster ontwikkelt een veilig mechanisch device voor hartondersteuning bij acuut hartfalen, met focus op haalbaarheid en validatie via testen en samenwerking met derden.

€ 20.000
Mkb-innovati...

SPARK - Subcutaneous Pump and Advanced Remote Kit

Het project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen.

€ 199.138
Mkb-innovati...

CLOBT: Cardiale Levensreddende Ondersteuning Booster Techno

CardiacBooster heeft een innovatief apparaat ontwikkeld dat het hart van binnenuit ondersteunt, met betere resultaten en minder risico's dan bestaande mechanische ondersteuningssystemen voor cardiogene shockpatiënten.

€ 155.376
EIC Transition

Novel microsensing platform for remote patient monitoring

The FORESEE project aims to advance implantable microstimulators for remote monitoring of chronic heart failure, enhancing patient care and market access for 10.5 million potential users.

€ 2.499.051
ERC Starting...

Surgical optogenetic bioprinting of engineered cardiac muscle

LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.

€ 1.499.705